Bart A. Ploeger
Berlin, BE, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma.
Journal: Hepatology (Baltimore, Md.)
Published: March 14, 2025
Zabedosertib, a novel interleukin-1 receptor-associated kinase-4 inhibitor, shows a favorable pharmacokinetic and safety profile across multiple phase 1 studies.
Journal: Frontiers in pharmacology
Published: November 01, 2024
Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 06, 2023
Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study.
Journal: EClinicalMedicine
Published: October 17, 2022
Clinical Pharmacokinetics and Pharmacodynamics of the Selective Progesterone Receptor Modulator Vilaprisan: A Comprehensive Overview.
Journal: Clinical pharmacokinetics
Published: August 27, 2021
Point-of-care testing in out-of-hospital cardiac arrest: a retrospective analysis of relevance and consequences.
Journal: Scandinavian journal of trauma, resuscitation and emergency medicine
Published: May 03, 2021
Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies.
Journal: European journal of cancer (Oxford, England : 1990)
Published: February 19, 2021
Assessment of the safe and efficacious dose of the selective progesterone receptor modulator vilaprisan for the treatment of patients with uterine fibroids by exposure-response modelling and simulation.
Journal: British journal of clinical pharmacology
Published: February 18, 2021
NT-proBNP Qualifies as a Surrogate for Clinical End Points in Heart Failure.
Journal: Clinical pharmacology and therapeutics
Published: September 08, 2020
Population pharmacokinetics of regorafenib in solid tumours: Exposure in clinical practice considering enterohepatic circulation and food intake.
Journal: British journal of clinical pharmacology
Published: December 18, 2019
Population Pharmacokinetic and Exposure-Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease.
Journal: Clinical pharmacokinetics
Published: October 05, 2019
Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial.
Journal: Targeted oncology
Published: October 02, 2019
Last Updated: 09/26/2026